Nebivolol
Bystolic (nebivolol hydrochloride)
Approved Indications & Off-Label Uses
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults | Monotherapy or combination | FDA Approved |
Nebivolol is a third-generation, highly beta-1 selective adrenergic blocker distinguished from older agents by its unique dual mechanism: d-nebivolol provides potent beta-1 blockade (with beta receptor affinity greater than 1000-fold higher than the l-isomer), while l-nebivolol stimulates endothelial nitric oxide (NO) release, producing peripheral vasodilation. At low doses (≤10 mg) in extensive metabolizers, nebivolol maintains excellent beta-1 selectivity, but this selectivity diminishes at higher doses and in poor metabolizers. This combination reduces peripheral vascular resistance without the reduction in cardiac output that characterizes traditional beta-blockers. Although nebivolol’s only FDA-approved indication in the United States is hypertension, it has regulatory approval for heart failure in Europe (based on the SENIORS trial) and is increasingly used off-label for rate control and other cardiovascular conditions. Nebivolol was not studied in patients with angina pectoris or recent MI.
Heart failure in the elderly (≥70 years) — The SENIORS trial (n=2,128) showed nebivolol reduced the composite of all-cause mortality or cardiovascular hospital admission by 14% (HR 0.86, p=0.039). Approved for stable HF in elderly patients in Europe but not in the US. Nebivolol is NOT one of the three evidence-based HFrEF beta-blockers per 2022 AHA/ACC/HFSA guidelines. Evidence quality: Moderate–High.
Rate control in atrial fibrillation — Used for ventricular rate control given once-daily dosing and long half-life. Evidence quality: Moderate.
Hypertension with erectile dysfunction concerns — Nebivolol has shown favorable effects on erectile function compared with other beta-blockers, likely related to NO-mediated vasodilation. Evidence quality: Moderate.
Dosing by Clinical Scenario
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Essential hypertension — monotherapy | 5 mg once daily | 5–20 mg once daily | 40 mg once daily | Increase at 2-week intervals; take with or without food; a more frequent dosing regimen is unlikely to be beneficial Beta-1 selectivity is dose-dependent: maintained at ≤10 mg in EMs, diminishes at higher doses |
| Hypertension — combination therapy | 5 mg once daily | 5–20 mg once daily | 40 mg once daily | Additive with ACEi, ARBs, and thiazide diuretics; no pharmacokinetic interactions with ramipril, losartan, HCTZ, furosemide, or spironolactone |
| Heart failure in elderly ≥70 years (off-label, SENIORS protocol) | 1.25 mg once daily | Titrate: double dose q2wk to target 10 mg once daily | 10 mg once daily | Per SENIORS protocol; mean maintenance dose achieved was 7.7 mg; irrespective of ejection fraction; not FDA-approved for this indication in the US |
Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe renal impairment (CrCl <30 mL/min) | 2.5 mg once daily | Titrate slowly | Individualize | Renal clearance decreased; not studied in dialysis patients; hemodialysis not expected to enhance clearance due to high protein binding (~98%) |
| Moderate hepatic impairment | 2.5 mg once daily | Titrate slowly | Individualize | Metabolism decreased; not studied in severe hepatic impairment |
| Severe hepatic impairment (Child-Pugh >B) | CONTRAINDICATED. Nebivolol is the only beta-blocker with severe hepatic impairment as a formal contraindication. | |||
| Elderly (≥65 years) | No dose adjustment necessary based on age alone. No overall differences in efficacy or adverse events between older and younger patients in US hypertension trials. | |||
| CYP2D6 poor metabolizers | No dose adjustment necessary. Despite 5-fold higher Cmax and 10-fold higher AUC of d-nebivolol in PMs, the clinical effect and safety profile were similar to extensive metabolizers. | |||
Nebivolol is metabolized by CYP2D6, and poor metabolizers achieve markedly higher plasma levels (5x Cmax, 10x AUC for d-nebivolol). However, unlike most CYP2D6-dependent drugs, no dose adjustment is needed for PMs because the hydroxyl and glucuronide metabolites are also pharmacologically active and contribute to the overall beta-blocking effect. The clinical effect and safety profile are similar regardless of CYP2D6 phenotype. What does matter clinically is co-administration with strong CYP2D6 inhibitors like fluoxetine, which causes an 8-fold AUC and 3-fold Cmax increase — in this scenario, monitor BP closely and reduce the nebivolol dose as needed.
Pharmacology
Mechanism of Action
Nebivolol is a racemic mixture of d-nebivolol and l-nebivolol with a dual mechanism of action that distinguishes it from all other beta-blockers. The d-isomer is a highly selective beta-1 adrenergic antagonist with the strongest beta-1 receptor affinity of any clinically available beta-blocker — approximately 3.5 times more selective than bisoprolol. At therapeutic doses, d-nebivolol reduces heart rate, myocardial contractility, and AV conduction velocity without significant beta-2 blockade. The l-isomer stimulates the endothelial L-arginine/nitric oxide (NO) pathway, causing NO-dependent vasodilation that reduces peripheral vascular resistance. This vasodilatory property preserves cardiac output and stroke volume during beta-blockade, resulting in a hemodynamic profile distinct from traditional beta-blockers. The combined effect is blood pressure reduction through both decreased cardiac output and decreased peripheral resistance, with maintained or improved endothelial function.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Absorption similar to oral solution; absolute bioavailability not determined; Tmax 1.5–4 h in both EMs and PMs; food does not affect PK | Consistent absorption regardless of food; once-daily dosing with or without meals |
| Distribution | Protein binding ~98% (albumin); d-nebivolol plasma levels proportional to dose up to 20 mg; l-nebivolol exposure higher but contributes minimally to beta-blocking activity | High protein binding means hemodialysis is not expected to enhance clearance; no clinically significant displacement interactions with warfarin, digoxin, or diuretics |
| Metabolism | Primarily via glucuronidation; secondarily via CYP2D6 (N-dealkylation and oxidation); hydroxyl and glucuronide metabolites are pharmacologically active; d-nebivolol t½ ~12 h (EMs) / ~19 h (PMs) | CYP2D6 phenotype affects plasma levels (PMs: 5x Cmax, 10x AUC) but not clinical efficacy or safety; CYP2D6 inhibitors (fluoxetine, paroxetine) substantially increase exposure |
| Elimination | Urine ~35% / feces ~44% (in EMs); PMs excrete ~67% in urine and ~13% in feces; d-nebivolol accumulates ~1.5-fold with daily dosing in EMs | Balanced elimination in EMs; predominantly renal in PMs; severe renal impairment reduces clearance (start 2.5 mg); moderate hepatic impairment reduces metabolism (start 2.5 mg) |
Nebivolol Side Effects
| Adverse Effect | Incidence (5 / 10 / 20–40 mg) | Placebo | Clinical Note |
|---|---|---|---|
| Headache | 9% / 6% / 7% | 6% | Most commonly reported adverse effect; not clearly dose-related; usually mild and transient; comparable to placebo at 10 mg dose |
| Fatigue | 2% / 2% / 5% | 1% | Clearly dose-related; at 5–10 mg rates are modest (2%); at higher doses (20–40 mg) increases to 5% |
| Dizziness | 2% / 3% / 4% | 2% | Dose-related; counsel patients to rise slowly; at 5 mg dose, rate is equivalent to placebo |
| Diarrhea | 2% / 2% / 3% | 2% | Marginally above placebo; dose-related only at highest dose group; usually self-limiting |
| Nausea | 1% / 3% / 2% | 0% | Second most common cause of discontinuation (0.2%); peaks at 10 mg; take with food if symptomatic |
| Bradycardia | 0% / 0% / 1% | 0% | Only reached ≥1% at highest dose group (20–40 mg); third most common cause of discontinuation (0.2%) |
| Insomnia | 1% / 1% / 1% | 0% | Despite lipophilicity, rates are low; generally mild |
| Chest pain | 0% / 1% / 1% | 0% | Evaluate for cardiac etiology; may represent reduced myocardial perfusion at higher beta-blocking doses |
| Peripheral edema | 1% / 1% / 1% | 0% | Monitor for signs of worsening cardiac function |
| Dyspnea | 0% / 1% / 1% | 0% | Evaluate for bronchospasm or worsening heart failure; dose-dependent loss of beta-1 selectivity may contribute |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Symptomatic bradycardia | ≤1% (trials); postmarketing reports | Days to weeks | Reduce dose or hold; IV atropine; isoproterenol cautiously; pacing if refractory |
| AV block (2nd/3rd degree) | Postmarketing only | Days to weeks | Discontinue; atropine or isoproterenol; pacing if needed |
| Acute pulmonary edema | Postmarketing only | Variable | Discontinue; IV diuretics; supplemental oxygen; evaluate cardiac function |
| Acute renal failure | Postmarketing only | Variable | Discontinue; IV fluids; nephrology consultation |
| Bronchospasm | Postmarketing only | Any time; more likely at higher doses | Beta-2 agonist; reduce or discontinue; patients with bronchospastic disease should generally not receive beta-blockers |
| Rebound angina/MI on abrupt withdrawal | Class effect | 1–14 days post-discontinuation | Taper over 1–2 weeks; reinstate promptly if rebound symptoms; note: nebivolol was NOT studied in patients with angina or recent MI |
Nebivolol’s tolerability profile is among the most favorable of all beta-blockers. In controlled hypertension trials, the discontinuation rate (2.8%) was only marginally higher than placebo (2.2%). Meta-analyses of controlled trials found no significant difference in the overall frequency of adverse events between nebivolol and placebo. The NO-mediated vasodilation may explain the lower incidence of typical beta-blocker side effects (cold extremities, fatigue, erectile dysfunction) compared with traditional agents. The SENIORS trial confirmed good tolerability in elderly heart failure patients over a median 21-month follow-up.
Drug Interactions
Nebivolol is metabolized via CYP2D6, making it susceptible to pharmacokinetic interactions with CYP2D6 inhibitors — a critical distinction from atenolol and bisoprolol (which bypass this pathway). However, nebivolol itself does not inhibit any CYP pathways. No clinically significant interactions were found with digoxin, warfarin, diuretics (furosemide, HCTZ, spironolactone), ramipril, or losartan.
No clinically relevant pharmacokinetic interactions documented with: digoxin, warfarin, furosemide, hydrochlorothiazide, spironolactone, ramipril, losartan, ranitidine, or activated charcoal. Population PK analyses also found no interaction with acetaminophen, aspirin, atorvastatin, esomeprazole, ibuprofen, levothyroxine, metformin, sildenafil, simvastatin, or tocopherol. Nebivolol does not inhibit any CYP pathways at therapeutic concentrations.
Monitoring Parameters
- Heart RateEvery visit
RoutineBradycardia occurred in ≤1% at 20–40 mg; hold or reduce dose if HR <50 bpm with symptoms. - Blood PressureEvery visit; during titration
RoutineTitrate q2wk based on BP response. Monitor closely when co-administered with CYP2D6 inhibitors, which can substantially increase nebivolol exposure. - Renal FunctionBaseline; periodically
RoutineCrCl <30 requires reduced starting dose (2.5 mg). Nebivolol was associated with increased BUN in controlled trials. Acute renal failure reported postmarketing. - Hepatic FunctionBaseline if liver disease suspected
Trigger-basedModerate impairment: start 2.5 mg. Severe impairment (Child-Pugh >B): contraindicated. Abnormal hepatic function (increased AST, ALT, bilirubin) reported postmarketing. - Blood GlucosePeriodically in diabetics
RoutineMay prevent early warning signs of hypoglycemia (tachycardia) and increase risk for severe or prolonged hypoglycemia, especially in patients who are fasting. - Lipids & PlateletsPeriodically
RoutineControlled trials showed increased uric acid, triglycerides and decreased HDL cholesterol and platelet count. Monitor in patients with baseline abnormalities.
Contraindications & Cautions
Absolute Contraindications
- Severe bradycardia
- Heart block greater than first degree (without a functioning pacemaker)
- Cardiogenic shock
- Decompensated cardiac failure
- Sick sinus syndrome (unless a permanent pacemaker is in place)
- Severe hepatic impairment (Child-Pugh >B) — unique to nebivolol among beta-blockers
- Hypersensitivity to any component of the product
Relative Contraindications (Specialist Input Recommended)
- Bronchospastic diseases — patients with bronchospastic disease should generally not receive beta-blockers; nebivolol’s high beta-1 selectivity at low doses offers a theoretical advantage but is not sufficient to recommend use in active asthma
- Pheochromocytoma — initiate an alpha-blocker before starting any beta-blocker
- Peripheral vascular disease — beta-blockers can precipitate or aggravate arterial insufficiency symptoms
Use with Caution
- Diabetes mellitus — may mask tachycardia and other warning signs of hypoglycemia; may increase risk for severe or prolonged hypoglycemia in patients who are fasting
- Thyrotoxicosis — may mask tachycardia; abrupt withdrawal may precipitate thyroid storm
- Moderate hepatic impairment — start at 2.5 mg; monitor closely
- Severe renal impairment (CrCl <30) — start at 2.5 mg; not studied in dialysis
- Co-administration with CYP2D6 inhibitors — may need dose reduction
- Major surgery — do not routinely withdraw chronic beta-blocker therapy preoperatively
- History of severe anaphylaxis — patients may be more reactive and unresponsive to epinephrine
Do not abruptly discontinue nebivolol in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias have been reported following sudden withdrawal of beta-blockers. Taper over 1 to 2 weeks when possible. If angina worsens or acute coronary insufficiency develops, reinstate nebivolol promptly. Note: nebivolol was not studied in patients with angina pectoris or who had a recent MI.
Patient Counselling
Purpose of Therapy
Nebivolol lowers your blood pressure by slowing your heart rate and relaxing your blood vessels. This dual action reduces the workload on your heart and helps protect your blood vessels.
How to Take
Take nebivolol once daily at the same time each day. It can be taken with or without food. Do not stop taking this medication suddenly without consulting your doctor, as doing so can cause serious heart problems. Your doctor will gradually reduce your dose if the medication needs to be stopped.
Sources
- Bystolic (nebivolol) tablets — FDA-approved prescribing information (revised June 2023). accessdata.fda.govPrimary US regulatory source for hypertension dosing, adverse reaction Table 1 incidence data, CYP2D6 interaction data (fluoxetine 8x AUC), and hepatic/renal dosing adjustments.
- Bystolic (nebivolol) tablets — FDA prescribing information (2017 revision). accessdata.fda.govCross-reference for pharmacokinetic data, CYP2D6 poor metabolizer characterization, and drug-drug interaction studies with warfarin, digoxin, and diuretics.
- Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi:10.1093/eurheartj/ehi115Landmark trial (n=2,128; age ≥70) showing 14% reduction in composite all-cause mortality or CV hospital admission with nebivolol (HR 0.86, p=0.039); irrespective of ejection fraction.
- van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction (SENIORS sub-analysis). J Am Coll Cardiol. 2009;53(23):2150–2158. doi:10.1016/j.jacc.2009.02.046SENIORS sub-analysis showing nebivolol was effective in patients with both impaired and preserved ejection fraction; supports use regardless of LVEF in elderly HF.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline; beta-blockers not first-line for uncomplicated hypertension but remain indicated with compelling indications.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012Specifies carvedilol, bisoprolol, and metoprolol succinate as the 3 evidence-based beta-blockers for HFrEF; nebivolol is NOT included despite SENIORS trial data.
- Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol. 2009;54(2):123–128. doi:10.1097/FJC.0b013e3181ad207bReview of nebivolol’s unique NO-mediated vasodilatory mechanism, d/l-isomer pharmacology, and favorable metabolic and endothelial profile.
- Kamp O, Metra M, Bugatti S, et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs. 2010;70(1):41–56. doi:10.2165/11530710-000000000-00000Comprehensive review of nebivolol’s hemodynamic profile: preserved cardiac output, reduced peripheral resistance, and maintained stroke volume during beta-blockade.
- Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2007;63(5):575–582. doi:10.1111/j.1365-2125.2006.02796.xKey clinical study demonstrating that CYP2D6 polymorphisms significantly affect nebivolol PK (10–15x higher plasma levels in PMs) but not antihypertensive efficacy or tolerability.
- Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009;11(9):872–880. doi:10.1093/eurjhf/hfp104SENIORS sub-analysis confirming nebivolol is safe and effective across the full spectrum of renal function in elderly HF patients.